(Q40256137)

18 September 2017

1 reference

title

Captopril: clinical pharmacology and benefit-to-risk ratio in hypertension and congestive heart failure (English)

1 reference

18 September 2017

1 reference

congestive heart failure

1 reference

Vlasses PH

1

1 reference

18 September 2017

Ferguson RK

series ordinal

2

1 reference

18 September 2017

Chatterjee K

series ordinal

3

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 January 1982

1 reference

18 September 2017

1 reference

18 September 2017

2

1 reference

18 September 2017

1

1 reference

18 September 2017

1-17

1 reference

Inhibition of brain angiotensin-1 converting enzyme by Bothrops jararaca nonapeptide (SQ 20881) and a prolyl analog (SQ 14225)

18 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Effects of SQ 14,225, an orally active inhibitor of angiotensin-converting enzyme on blood pressure, heart rate and plasma renin activity of conscious normotensive dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Inhibition of angiotensin converting enzyme by SQ 14,225 in conscious rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

The effects of kininase II inhibition by SQ 14225 on kidney kallikrein-kinin and prostaglandin systems in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Reciprocal relation between renin dependency and sodium dependency in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

A specific orally active inhibitor of angiotensin-converting enzyme in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Converting enzyme inhibition with an orally active compound in hypertensive man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Endocrine factors in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Improvement of chronic congestive heart-failure by oral captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Angiotensin II, Digital Blood Flow, and the Precapillary and Postcapillary Blood Vessels of Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Effect of Captopril on Renal Vascular Tone in Patients with Essential Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Treatment of Chronic Congestive Heart Failure with Captopril, an Oral Inhibitor of Angiotensin-Converting Enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Response of Arterial Blood Pressure, Plasma Renin Activity and Plasma Aldosterone Concentration to Long-Term Administration of Captopril in Patients with Severe, Treatment-Resistant Malignant Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Prior receptor occupancy as a determinant of the pressor activity of infused angiotensin II in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

The role of vasodilator therapy in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Taste loss associated with captopril treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Captopril-induced pemphigus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Neurological dysfunction in two patients receiving captopril and cimetidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

Use of the oral angiotensin I-converting enzyme inhibitor(captopril) in childhood malignant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03167.X

10.1002/J.1875-9114.1982.TB03167.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference